Landiolol

Drug Profile

Landiolol

Alternative Names: Corebeta; Low-dose landiolol; ONO-1101; Onoact; Onoact 50

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Ono Pharmaceutical
  • Class Antiarrhythmics; Morpholines; Small molecules; Urea compounds
  • Mechanism of Action Beta 1 adrenergic receptor antagonists; Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Arrhythmias; Coronary disorders; Supraventricular tachycardia
  • Phase II/III Ventricular arrhythmias

Most Recent Events

  • 01 Mar 2016 Ono Pharmaceutical initiates enrolment in a clinical trial for Coronary disorders (Diagnosis) in Japan (UMIN000020432)
  • 01 Jun 2015 Phase-II/III clinical trials in Ventricular arrhythmias in Japan (IV) (JapicCTI-152956)
  • 07 Apr 2014 Launched for Arrhythmias (tachyarrhythmia during and after operation in low cardiac function) in Japan (Intravenous) prior to April 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top